1. How cannabis medicines gained legitimacy

    Interviewee/Contributer: Roger Pertwee

    Organisation: University of Aberdeen

    Read more

  2. UK Biotech needs a subtle culture shift

    Interviewee/Contributer: Karen Finn

    Organisation: Mednous

    Read more

  3. Investment pendulum swings back towards biotech

    Interviewee/Contributer: Bart Bergstein

    Organisation: Forbion Capital Partners

    Read more

  4. Europe to tackle antimicrobial resistance

    Interviewee/Contributer: Nigel Gaymond

    Organisation: 

    Read more

  5. The perilous state of antibiotic development

    Interviewee/Contributer: Helen Boucher

    Organisation: Infectious Diseases Society of America (IDSA)

    Read more

  6. Risk sharing with Pharma -- is this the way to go?

    Interviewee/Contributer: Onno van de Stolpe

    Organisation: Galapagos NV

    Read more

  7. ADCs propelled back into the oncology spotlight

    Interviewee/Contributer: Karen Finn

    Organisation: MedNous

    Read more

  8. Why Oxford BioTherapeutics is targeting ADCs

    Interviewee/Contributer: Christian Rohlff

    Organisation: Oxford BioTherapeutics Ltd

    Read more

  9. How developers approach antibody drug conjugates

    Interviewee/Contributer: Bruno Pagliara

    Organisation: On-kòs Pharma Consulting

    Read more

  10. The art of tapping into academic expertise

    Interviewee/Contributer: Jane Buus Laursen

    Organisation: AstraZeneca

    Read more